Maureen Ann Smythe Pharm.D.

Maureen Ann Smythe Pharm.D.


Professor (Clinical)


Pharmacy Practice

Office Location

EACPHS, Room 4126




Maureen Ann Smythe Pharm.D.

Degrees and Certifications

  • Pharm.D., Wayne State University, 1987
  • B. Pharm., Wayne State University, 1986
  • Critical Care Fellowship, Henry Ford Hospital, 1988

Positions and Employment

  • Professor (Clinical), Wayne State University, 2001-present
  • Associate Professor, Wayne State University. 1994-2001
  • Assistant Professor, Wayne State University. 1988-1994

Awards and Honors

  • Outstanding Achievement in Clinical Sciences Research, Wayne State University, Eugene Applebaum College of Pharmacy & Health Sciences, 2012
  • Preceptor of the Year, William Beaumont Hospital, LAPP Class of 2007
  • Teacher of the Year, Wayne State University, Professional 3rd year class, 2005
  • Teacher of the Year, Wayne State University, Professional 3rd year class, 2004

Areas of Expertise

  • Anticoagulation
  • Critical care therapeutics

Primary Research Interest

  • Anticoagulation management
  • Thrombosis
  • Critical care therapeutics

Recent Publications

  1. Smythe MA, Forman MJ, Bertran EA, Hoffman JL, Priziola JL, Koerber JM. Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes of atrial fibrillation patients; J Thromb Thrombolysis 2015;40:280-287.
  2. Smythe MA, Priziola J, Dobesh PP, Wirth D, Cuker A, Wittkowsky AK. Practical management of heparin anticoagulants in adults, J Thromb Thrombolysis 2015; In Press
  3. Hoffman JL, Aneese JN, Schmidt KJ, Chaben AC, Smythe MA. Optimizing anticoagulation management through the use of a hospital engagement network metric for inpatient anticoagulant hemorrhage, Ann Pharmacother 2015; In Press
  4. Smythe MA, Forsyth L, Warkentin TE, Smith M, Sheppard JI, Shannon F. Progressive, Fatal Thrombosis associated with Heparin-Induced Thrombocytopenia following Cardiac Surgery Despite “Therapeutic Anticoagulation with Argatroban: Potential Role for PTT and ACT Confounding, J Cardiovasc Vasc Anesth 2014 , Aug 25 pii: S1053-0770(14)00187-6. doi: 10.1053/j.jvca.2014.04.029. [Epub ahead of print]
  5. Smythe MA, Koerber JM, Forsyth LL, Tuchscherer RM, Implications of heparin-induced thrombocytopenia overdiagnosis, Ann Pharmacother 2014; 48 (10):1394-1395.
  6. Burgos KD, Grant RF, Rutkowski D, DeCiantis V, Fodor E, Dadayan S, Smythe MA. Aligning experiential opportunities with institutional needs: Focus on chronic obstructive pulmonary disease; J Pharma Care Health Sys 2014; S1 (
  7. Smythe MA, Fanikos J, Gulseth MP, Wittkowsky AK, Spinler SA, Dager WE, Nutescu E. Rivaroxaban: Practical considerations of ensuring safety and efficacy, Pharmacotherapy 2013;33 (11):1223-45.